Current issues with platelet transfusion in patients with cancer

Area of Science:

• Hematology
• Oncology
• Transfusion Medicine

Background:

• Platelet transfusions have been a cornerstone in managing thrombocytopenia for three decades.
• The use of platelet transfusions has significantly increased, shifting from whole blood to apheresis, with hematology/oncology patients being major recipients due to chemotherapy-induced thrombocytopenia.

Purpose of the Study:

• To review the current landscape of platelet transfusion therapy.
• To highlight the challenges and risks associated with platelet transfusions, including infections, alloimmunization, donor recruitment difficulties, and high costs.
• To emphasize the need for alternative strategies to reduce or eliminate platelet transfusions in specific patient populations.

Main Methods:

• This review synthesizes existing literature on platelet transfusion practices and outcomes.
• It analyzes the indications, risks, and economic factors associated with platelet transfusions.
• The focus is on patients undergoing intensive chemotherapy or myeloablative regimens.

Main Results:

• Platelet transfusions effectively manage severe thrombocytopenia but carry risks of infection and alloimmunization.
• Prophylactic transfusion thresholds influence usage and cost, with higher thresholds reducing overall administration.
• Intensive chemotherapy regimens frequently necessitate multiple platelet transfusions for cancer patients.

Conclusions:

• While vital, platelet transfusions present significant challenges and risks.
• The high demand and associated costs underscore the urgent need for alternative therapeutic strategies.
• Developing methods to reduce or eliminate reliance on platelet transfusions is critical for improving patient care and managing healthcare resources.